Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in RLAY.
← Back to Free Index

RLAY

Analysis as of: 2026-05-14
Relay Therapeutics, Inc.
Clinical-stage biotechnology company developing small-molecule therapies for cancer and genetic disease using an integrated computational and experimental discovery engine.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical proof separates franchise value from platform optionality
The upside is meaningful but concentrated. One drug can turn computational credibility into real oncology economics, while one weak dataset can send the stock back toward cash value and residual platform hope.

Analysis

Thesis
If zovegalisib converts early promise into durable registrational proof in second-line breast cancer and opens a real vascular-anomalies pillar, Relay can rerate from a single-asset clinical story into an emerging precision-medicine franchise; the upside is real, but it still depends on proof more than platform narrative.
Last Economy Alignment
AI and cheaper computation should improve Relay's discovery throughput and data compounding, but value capture sits in owned molecules, clinical data, and regulatory progress rather than software seats. That makes Relay a moderate beneficiary of the Last Economy, not a core control point.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
The realistic optimistic case is a multi-bagger, not a moonshot. Relay has one lead asset with credible franchise potential, a second indication that could add meaningful breadth, and enough runway to reach several value-inflecting milestones. But biology, regulators, and concentration risk cap the odds of a clean hypergrowth outcome. That makes the stock attractive if proof lands, while keeping the outcome below the very best clinical-biotech upside paths.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is concentrated proof, not AI commoditization. Relay is primarily exposed to the chance that zovegalisib fails to preserve clear efficacy, safety, or regulatory momentum in larger, more consequential settings. Cash runway lowers near-term financing stress, but if proof or timing slips, dilution risk rises and valuation can fall back toward cash plus platform optionality.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.31
They use computation plus wet-lab science to design harder-to-drug molecules, so better AI should improve their hit rate over time. But they do not own an AI toll booth; biology, regulators, and the success of one lead asset still decide whether that advantage turns into durable value.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case